ALLK Key Statistics, Chart & Performance
The current stock price of ALLK is 0.3291 USD. In the past month the price increased by 1.89%. In the past year, price decreased by -77.15%.
ALLK Latest News, Press Relases and Analysis
ALLK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.09 | 402.18B | ||
| AMGN | AMGEN INC | 15.76 | 185.50B | ||
| GILD | GILEAD SCIENCES INC | 15.57 | 158.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.89 | 110.80B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.43 | 83.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 872.78 | 58.35B | ||
| INSM | INSMED INC | N/A | 43.23B | ||
| NTRA | NATERA INC | N/A | 32.54B | ||
| BIIB | BIOGEN INC | 10.87 | 26.67B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.51 | 22.09B | ||
| INCY | INCYTE CORP | 16.46 | 20.63B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.21B |
Related stock screener links
About ALLK
Company Profile
Allakos, Inc. engages in the development of therapeutic antibodies. The company is headquartered in San Carlos, California and currently employs 61 full-time employees. The company went IPO on 2018-07-19. The Company’s most advanced product candidate, AK006, is in a Phase I clinical trial. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. The company is developing AK006 for the treatment of CSU and potentially other indications. AK006 has completed preclinical testing, and in these studies, it has demonstrated that binding of AK006 to Siglec-6 inhibits multiple modes of mast cell activation, including IgE, IL-33, KIT, C5a and MRGPR-X2. In addition to mast cell inhibition, AK006 reduced human tissue mast cells via ADCP in the presence of activated macrophages. The firm is also developing lirentelimab (AK002) and, in conjunction with the Phase II, lirentelimab results in atopic dermatitis and chronic spontaneous urticaria.
Company Info
ALLAKOS INC
825 Industrial Road, Suite 500
San Carlos CALIFORNIA 94065 US
CEO: Robert Alexander
Employees: 131
Phone: 16505975002
ALLAKOS INC / ALLK FAQ
What does ALLK do?
Allakos, Inc. engages in the development of therapeutic antibodies. The company is headquartered in San Carlos, California and currently employs 61 full-time employees. The company went IPO on 2018-07-19. The Company’s most advanced product candidate, AK006, is in a Phase I clinical trial. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. The company is developing AK006 for the treatment of CSU and potentially other indications. AK006 has completed preclinical testing, and in these studies, it has demonstrated that binding of AK006 to Siglec-6 inhibits multiple modes of mast cell activation, including IgE, IL-33, KIT, C5a and MRGPR-X2. In addition to mast cell inhibition, AK006 reduced human tissue mast cells via ADCP in the presence of activated macrophages. The firm is also developing lirentelimab (AK002) and, in conjunction with the Phase II, lirentelimab results in atopic dermatitis and chronic spontaneous urticaria.
What is the current price of ALLK stock?
The current stock price of ALLK is 0.3291 USD. The price decreased by -0.06% in the last trading session.
Does ALLAKOS INC pay dividends?
ALLK does not pay a dividend.
How is the ChartMill rating for ALLAKOS INC?
ALLK has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting ALLK stock to perform?
10 analysts have analysed ALLK and the average price target is 1.26 USD. This implies a price increase of 282.25% is expected in the next year compared to the current price of 0.3291.
Would investing in ALLAKOS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ALLK.
What is ALLAKOS INC worth?
ALLAKOS INC (ALLK) has a market capitalization of 29.74M USD. This makes ALLK a Nano Cap stock.
ALLK Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to ALLK. When comparing the yearly performance of all stocks, ALLK is a bad performer in the overall market: 89.24% of all stocks are doing better.
ALLK Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALLK. While ALLK seems to be doing ok healthwise, there are quite some concerns on its profitability.
ALLK Financial Highlights
Over the last trailing twelve months ALLK reported a non-GAAP Earnings per Share(EPS) of -0.8. The EPS increased by 67.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -119.89% | ||
| ROE | -146.95% | ||
| Debt/Equity | 0 |
ALLK Forecast & Estimates
10 analysts have analysed ALLK and the average price target is 1.26 USD. This implies a price increase of 282.25% is expected in the next year compared to the current price of 0.3291.